A detailed history of E Fund Management (Hong Kong) Co., Ltd. transactions in Legend Biotech Corp stock. As of the latest transaction made, E Fund Management (Hong Kong) Co., Ltd. holds 53,710 shares of LEGN stock, worth $2.38 Million. This represents 1.57% of its overall portfolio holdings.

Number of Shares
53,710
Previous 58,426 8.07%
Holding current value
$2.38 Million
Previous $2.59 Million 1.16%
% of portfolio
1.57%
Previous 1.59%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 28, 2024

SELL
$43.55 - $59.88 $205,381 - $282,394
-4,716 Reduced 8.07%
53,710 $2.62 Million
Q2 2024

Jul 12, 2024

BUY
$39.5 - $57.22 $54,273 - $78,620
1,374 Added 2.41%
58,426 $2.59 Million
Q1 2024

Apr 24, 2024

SELL
$55.06 - $69.99 $376,885 - $479,081
-6,845 Reduced 10.71%
57,052 $3.2 Million
Q4 2023

Jan 05, 2024

BUY
$57.25 - $69.74 $637,650 - $776,764
11,138 Added 21.11%
63,897 $3.85 Million
Q3 2023

Oct 12, 2023

BUY
$63.16 - $76.5 $68,212 - $82,620
1,080 Added 2.09%
52,759 $3.54 Million
Q2 2023

Jul 18, 2023

SELL
$46.28 - $75.01 $149,669 - $242,582
-3,234 Reduced 5.89%
51,679 $3.57 Million
Q1 2023

Apr 21, 2023

BUY
$43.42 - $57.37 $950,029 - $1.26 Million
21,880 Added 66.24%
54,913 $2.65 Million
Q4 2022

Feb 01, 2023

BUY
$38.8 - $55.46 $931 - $1,331
24 Added 0.07%
33,033 $1.65 Million
Q3 2022

Oct 24, 2022

BUY
$38.15 - $57.1 $59,704 - $89,361
1,565 Added 4.98%
33,009 $1.35 Million
Q2 2022

Jul 13, 2022

BUY
$33.54 - $55.0 $165,050 - $270,655
4,921 Added 18.55%
31,444 $1.73 Million
Q1 2022

Apr 12, 2022

BUY
$31.02 - $48.18 $545,827 - $847,775
17,596 Added 197.11%
26,523 $1.08 Million
Q4 2021

Feb 07, 2022

BUY
$41.14 - $56.98 $367,256 - $508,660
8,927 New
8,927 $416,000

Others Institutions Holding LEGN

About Legend Biotech Corp


  • Ticker LEGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 167,403,008
  • Market Cap $7.41B
  • Description
  • Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multipl...
More about LEGN
Track This Portfolio

Track E Fund Management (Hong Kong) Co., Ltd. Portfolio

Follow E Fund Management (Hong Kong) Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of E Fund Management (Hong Kong) Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on E Fund Management (Hong Kong) Co., Ltd. with notifications on news.